查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1938207

短讀定序市場－全球產業規模、佔有率、趨勢、機會及預測（依產品、應用、最終用戶、地區及競爭格局分類，2021-2031年）

Short-Read Sequencing Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Product, By Application, By End User, By Region & Competition, 2021-2031F
出版日期: | 出版商: TechSci Research | 英文 185 Pages | 商品交期: 2-3個工作天內

價格

We offer 8 hour analyst time for an additional research. Please contact us for the details.

簡介目錄

全球短讀定序市場預計將從 2025 年的 70.3 億美元成長到 2031 年的 113.7 億美元，複合年成長率為 8.35%。

這種高通量調查方法通常產生75-300個鹼基對的DNA序列，其價值在於能夠以極高的準確度識別遺傳變異。該領域的發展主要得益於定序成本的快速下降以及基因組數據在腫瘤學和罕見疾病診斷臨床工作流程中的深度整合。近期監管趨勢也支持對基因組分析在治療選擇中日益成長的依賴。例如，個人化醫療聯盟報告稱，到2024年，美國食品藥物管理局（FDA）核准的新型治療分子實體中，約有38%將是個人化藥物。

市場概覽
預測期 2027-2031
市場規模：2025年 70.3億美元
市場規模：2031年 113.7億美元
複合年成長率：2026-2031年 8.35%
成長最快的細分市場 消耗品
最大的市場 北美洲

儘管存在這些成長要素，但該產業在管理和解讀現代定序平台產生的大量資料集方面仍面臨著許多挑戰。處理、儲存和分析這些海量基因組資訊所需的大規模計算基礎設施造成了生物資訊瓶頸。這個問題阻礙了原始數據快速轉化為可操作的臨床見解，並限制了該技術在資源匱乏環境中的廣泛應用。

市場促進因素

定序成本和每千兆鹼基成本的持續下降是全球短讀長定序市場的關鍵驅動力，有效地普及了高通量基因組數據的獲取。這一價格下降趨勢是由平台開發商之間的激烈競爭以及超高通量系統的引入所推動的，這些系統顯著降低了全基因組分析的經濟門檻。這種經濟效益的提升使得臨床檢查室和研究機構能夠在不增加預算的情況下，從標靶基因組分析過渡到全面的全基因組定序（WGS）。 Frontline Genomics 在 2025 年 3 月報導《百元基因組：極限在哪裡？ 》就是這一趨勢的一個顯著例證，該文章報告 Ultima Genomics 已實現了 80 美元的基因組測序。這一價格水準遠低於先前的基準，加速了常規臨床定序的可行性。

在降低成本的同時，大規模人群基因組學計畫的實施也帶來了對短讀長定序能力的空前需求，各國都在尋求從人群層面了解疾病感受性和遺傳變異。這些大規模專案需要強大的平台，能夠高速、準確地處理數十萬個樣本。例如，美國國立衛生研究院 (NIH) 於 2025 年 2 月宣布，其國家人群調查計畫「我們所有人」(All of Us) 的基因組資料集已擴展至包含超過 41.4 萬名參與者的全基因組序列。這種高通量定序活動的激增與產業收入直接相關。 Illumina 公司截至 2025 年 10 月的會計年度業績便印證了這一點，該公司當季營收達 10.8 億美元，證實了這種大規模基因組學需求正在產生持續的商業性影響。

市場挑戰

大型資料集的管理與解讀，即生物資訊瓶頸，仍是限制全球短讀長定序市場成長的一大挑戰。儘管基因組讀段的物理生成過程已實現高通量、低成本，但下游的計算分析成本仍高成本，技術難度也極大。這種不平衡造成了工作流程瓶頸，數據生成速度超過了資訊處理和解讀能力，從而有效地延緩了原始數據轉化為可操作的臨床報告。因此，缺乏足夠計算基礎設施的實驗室無法應對如此龐大的數據量，阻礙了該技術在社區醫院和其他資源匱乏環境中的廣泛應用。

這種資料處理的複雜性對採用者構成了嚴重的營運障礙。困難不僅體現在儲存容量上，也體現在所產生資訊的效用。根據皮斯托亞聯盟（Pistoia Alliance）預測，到2024年，54%的生命科學專業人士會將非結構化資料視為有效利用實驗結果的主要障礙。因此，與資料管理和生物資訊分析相關的高昂成本造成了市場摩擦，阻礙了短讀定序技術在標準診斷流程中的廣泛應用。

市場趨勢

非侵入性腫瘤學中液態生物檢體的廣泛應用，從根本上改變了短讀測序的需求結構，將臨床關注點從基於組織的診斷轉向基於血液的基因組分析。這一趨勢的驅動力在於循環腫瘤DNA (ctDNA) 分析在治療選擇和微量殘存疾病(MRD) 監測中日益成長的效用，而這需要高靈敏度的低頻突變檢測才能實現深度定序。與傳統切片檢查不同，這些非侵入性檢測能夠對腫瘤的長期演變進行頻繁監測，從而持續提升臨床檢查室的定序通量需求。這種轉變的商業性影響在診斷服務提供者的快速擴張中顯而易見。例如，Guardant Health 報告稱，截至2025年2月，其營收為7.39億美元，年增31%，這主要得益於臨床腫瘤檢測量增加20%。

同時，市場正向空間基因體學與多體學整合方向發展，超越了傳統的DNA批量分析，旨在捕捉基因組結構與細胞組織之間複雜的相互作用。這一趨勢融合了次世代定序、高解析度成像和蛋白質分析技術，使研究人員能夠繪製活體組織環境中的基因表現和細胞表現型圖譜。這種整合對於理解腫瘤微環境和免疫反應尤其重要，需要能夠同時處理基因組和蛋白質組數據的先進平台。創新者們正在迅速部署系統以滿足這一複雜的需求。例如，Element Biosciences公司於2025年7月宣布，其旗艦產品AVITI24 5D多組體學系統在商業化發布僅七個月後，全球安裝量已超過50台。

目錄

第1章概述

第2章調查方法

第3章執行摘要

第4章：客戶評價

第5章 全球短讀定序市場展望

  • 市場規模及預測
    • 按金額
  • 市佔率及預測
    • 依產品（設備、耗材、服務）分類
    • 按應用領域（全基因組定序、全EXOME定序、標靶定序和重定序等）
    • 按最終用戶（學術/研究機構、醫院/診所、製藥/生技公司、其他）
    • 按地區
    • 按公司（2025 年）
  • 市場地圖

6. 北美短讀長定序市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 北美洲：國家分析
    • 美國
    • 加拿大
    • 墨西哥

7. 歐洲短讀長定序市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 歐洲：國家分析
    • 德國
    • 法國
    • 英國
    • 義大利
    • 西班牙

8. 亞太地區短讀長定序市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 亞太地區：國家分析
    • 中國
    • 印度
    • 日本
    • 韓國
    • 澳洲

9. 中東和非洲短讀定序市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 中東和非洲：國家分析
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 南非

10. 南美洲短讀長定序市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 南美洲：國家分析
    • 巴西
    • 哥倫比亞
    • 阿根廷

第11章 市場動態

  • 促進要素
  • 任務

第12章 市場趨勢與發展

  • 併購
  • 產品發布
  • 最新進展

第13章 全球短讀長定序市場：SWOT分析

第14章 波特五力分析

  • 產業競爭
  • 新進入者的可能性
  • 供應商電力
  • 顧客權力
  • 替代品的威脅

第15章 競爭格局

  • Illumina, Inc.
  • Invitae Corporation
  • Thermo Fisher Scientific, Inc.
  • Pacific Biosciences of California, Inc.
  • BGI Genomics Co., Ltd
  • QIAGEN NV
  • Agilent Technologies, Inc.
  • Azenta US, Inc.
  • PerkinElmer, Inc.
  • ProPhase Labs, Inc.

第16章 策略建議

第17章：關於研究公司及免責聲明

簡介目錄
Product Code: 23860

The Global Short-Read Sequencing Market is projected to expand from USD 7.03 Billion in 2025 to USD 11.37 Billion by 2031, reflecting a CAGR of 8.35%. This high-throughput methodology, which produces DNA reads typically between 75 and 300 base pairs, is prized for its ability to identify genetic variants with exceptional accuracy. Growth in this sector is primarily fueled by the precipitous decline in sequencing costs and the deepening integration of genomic data into clinical workflows for oncology and rare disease diagnostics. Recent regulatory trends underscore this increasing reliance on genomic profiling for treatment selection; for instance, the Personalized Medicine Coalition reported that personalized medicines comprised approximately 38 percent of new therapeutic molecular entities approved by the Food and Drug Administration in 2024.

Market Overview
Forecast Period2027-2031
Market Size 2025USD 7.03 Billion
Market Size 2031USD 11.37 Billion
CAGR 2026-20318.35%
Fastest Growing SegmentConsumables
Largest MarketNorth America

Despite these positive growth drivers, the industry faces a significant impediment regarding the management and interpretation of the massive datasets produced by modern sequencing platforms. The extensive computational infrastructure needed to process, store, and analyze these vast volumes of genomic information creates a bioinformatic bottleneck. This issue complicates the rapid translation of raw data into actionable clinical insights and limits the technology's broader adoption in environments constrained by limited resources.

Market Driver

The persistent decline in sequencing costs and per-gigabase expenses acts as a primary catalyst for the Global Short-Read Sequencing Market, effectively democratizing access to high-throughput genomic data. This downward pricing trajectory is driven by fierce competition among platform developers and the introduction of ultra-high-throughput systems that significantly reduce the financial barrier for whole-genome analysis. Such economic efficiency allows clinical laboratories and research institutions to transition from targeted panels to comprehensive whole-genome sequencing (WGS) without increasing their budgets. Highlighting this trend, Frontline Genomics reported in a March 2025 article titled 'The $100 Genome: Where's the Limit?' that Ultima Genomics achieved an $80 genome, a price point that substantially undercuts historical benchmarks and accelerates the feasibility of routine clinical sequencing.

Concurrent with these cost reductions, the implementation of large-scale population genomics programs is generating unprecedented demand for short-read sequencing capacity as nations aim to characterize disease susceptibility and genetic diversity at a population level. These massive initiatives require robust platforms capable of processing hundreds of thousands of samples with high speed and accuracy. For example, the National Institutes of Health announced in February 2025 that the All of Us Research Program had expanded its genomic dataset to include whole genome sequences from over 414,000 participants. This surge in high-volume sequencing activity directly translates into substantial industrial revenue, as evidenced by Illumina's October 2025 financial report, which announced quarterly revenue of $1.08 billion, underscoring the sustained commercial impact of these large-scale genomic demands.

Market Challenge

The management and interpretation of massive datasets, often termed the bioinformatic bottleneck, stands as a critical challenge inhibiting the growth of the Global Short-Read Sequencing Market. While the physical process of generating genomic reads has achieved high throughput at lower costs, downstream computational analysis remains disproportionately expensive and technically demanding. This disparity creates a workflow paralysis where data production outpaces the capacity to process and interpret the information, effectively delaying the translation of raw DNA sequences into actionable clinical reports. Consequently, laboratories lacking substantial computational infrastructure struggle to handle this influx of data, which restricts the technology's expansion into community hospitals and resource-constrained settings.

This complexity in data handling creates a severe operational barrier that deters potential adopters who cannot afford the necessary specialized IT resources. The difficulty lies not only in storage volume but also in the usability of the generated information. According to the Pistoia Alliance, 54 percent of life science professionals in 2024 cited unstructured data as a primary barrier to utilizing experimental findings effectively. As a result, the market experiences friction as the high indirect costs associated with data curation and bioinformatic analysis discourage the broader integration of short-read sequencing into standard diagnostic procedures.

Market Trends

The proliferation of liquid biopsy for non-invasive oncology is fundamentally altering the demand landscape for short-read sequencing by shifting clinical focus from tissue-based diagnostics to blood-based genomic profiling. This trend is driven by the increasing utility of circulating tumor DNA (ctDNA) analysis for therapy selection and minimal residual disease (MRD) monitoring, which requires deep sequencing coverage to detect low-frequency variants with high sensitivity. Unlike traditional biopsies, these non-invasive assays allow for frequent longitudinal monitoring of tumor evolution, thereby creating a sustained stream of sequencing throughput requirements for clinical laboratories. The commercial impact of this shift is evident in the rapid scaling of diagnostic providers; for instance, Guardant Health reported a 31 percent year-over-year revenue increase to $739 million in February 2025, supported by a 20 percent growth in clinical oncology test volumes.

Simultaneously, the market is expanding into spatial genomics and multi-omics integration, moving beyond bulk DNA analysis to capture the complex interplay between genomic architecture and cellular organization. This trend involves the convergence of next-generation sequencing with high-resolution imaging and protein analysis, allowing researchers to map gene expression and cellular phenotypes within their native tissue context. This integration is particularly critical for understanding tumor microenvironments and immune responses, necessitating advanced platforms that can simultaneously process genomic and proteomic data. Innovators are rapidly deploying systems to meet this complex demand; for example, Element Biosciences announced in July 2025 that it had installed over 50 units of its flagship AVITI24 5D Multiomic System globally within just seven months of its commercial launch.

Key Market Players

  • Illumina, Inc.
  • Invitae Corporation
  • Thermo Fisher Scientific, Inc.
  • Pacific Biosciences of California, Inc.
  • BGI Genomics Co., Ltd
  • QIAGEN NV
  • Agilent Technologies, Inc.
  • Azenta US, Inc.
  • PerkinElmer, Inc.
  • ProPhase Labs, Inc.

Report Scope

In this report, the Global Short-Read Sequencing Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Short-Read Sequencing Market, By Product

  • Instruments
  • Consumables
  • Services

Short-Read Sequencing Market, By Application

  • Whole Genome Sequencing
  • Whole Exome Sequencing
  • Targeted Sequencing & Resequencing
  • Others

Short-Read Sequencing Market, By End User

  • Academic & Research Institutes
  • Hospitals & Clinics
  • Pharmaceutical & Biotechnology Companies
  • Others

Short-Read Sequencing Market, By Region

  • North America
    • United States
    • Canada
    • Mexico
  • Europe
    • France
    • United Kingdom
    • Italy
    • Germany
    • Spain
  • Asia Pacific
    • China
    • India
    • Japan
    • Australia
    • South Korea
  • South America
    • Brazil
    • Argentina
    • Colombia
  • Middle East & Africa
    • South Africa
    • Saudi Arabia
    • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Short-Read Sequencing Market.

Available Customizations:

Global Short-Read Sequencing Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

  • Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

  • 1.1. Market Definition
  • 1.2. Scope of the Market
    • 1.2.1. Markets Covered
    • 1.2.2. Years Considered for Study
    • 1.2.3. Key Market Segmentations

2. Research Methodology

  • 2.1. Objective of the Study
  • 2.2. Baseline Methodology
  • 2.3. Key Industry Partners
  • 2.4. Major Association and Secondary Sources
  • 2.5. Forecasting Methodology
  • 2.6. Data Triangulation & Validation
  • 2.7. Assumptions and Limitations

3. Executive Summary

  • 3.1. Overview of the Market
  • 3.2. Overview of Key Market Segmentations
  • 3.3. Overview of Key Market Players
  • 3.4. Overview of Key Regions/Countries
  • 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Short-Read Sequencing Market Outlook

  • 5.1. Market Size & Forecast
    • 5.1.1. By Value
  • 5.2. Market Share & Forecast
    • 5.2.1. By Product (Instruments, Consumables, Services)
    • 5.2.2. By Application (Whole Genome Sequencing, Whole Exome Sequencing, Targeted Sequencing & Resequencing, Others)
    • 5.2.3. By End User (Academic & Research Institutes, Hospitals & Clinics, Pharmaceutical & Biotechnology Companies, Others)
    • 5.2.4. By Region
    • 5.2.5. By Company (2025)
  • 5.3. Market Map

6. North America Short-Read Sequencing Market Outlook

  • 6.1. Market Size & Forecast
    • 6.1.1. By Value
  • 6.2. Market Share & Forecast
    • 6.2.1. By Product
    • 6.2.2. By Application
    • 6.2.3. By End User
    • 6.2.4. By Country
  • 6.3. North America: Country Analysis
    • 6.3.1. United States Short-Read Sequencing Market Outlook
      • 6.3.1.1. Market Size & Forecast
        • 6.3.1.1.1. By Value
      • 6.3.1.2. Market Share & Forecast
        • 6.3.1.2.1. By Product
        • 6.3.1.2.2. By Application
        • 6.3.1.2.3. By End User
    • 6.3.2. Canada Short-Read Sequencing Market Outlook
      • 6.3.2.1. Market Size & Forecast
        • 6.3.2.1.1. By Value
      • 6.3.2.2. Market Share & Forecast
        • 6.3.2.2.1. By Product
        • 6.3.2.2.2. By Application
        • 6.3.2.2.3. By End User
    • 6.3.3. Mexico Short-Read Sequencing Market Outlook
      • 6.3.3.1. Market Size & Forecast
        • 6.3.3.1.1. By Value
      • 6.3.3.2. Market Share & Forecast
        • 6.3.3.2.1. By Product
        • 6.3.3.2.2. By Application
        • 6.3.3.2.3. By End User

7. Europe Short-Read Sequencing Market Outlook

  • 7.1. Market Size & Forecast
    • 7.1.1. By Value
  • 7.2. Market Share & Forecast
    • 7.2.1. By Product
    • 7.2.2. By Application
    • 7.2.3. By End User
    • 7.2.4. By Country
  • 7.3. Europe: Country Analysis
    • 7.3.1. Germany Short-Read Sequencing Market Outlook
      • 7.3.1.1. Market Size & Forecast
        • 7.3.1.1.1. By Value
      • 7.3.1.2. Market Share & Forecast
        • 7.3.1.2.1. By Product
        • 7.3.1.2.2. By Application
        • 7.3.1.2.3. By End User
    • 7.3.2. France Short-Read Sequencing Market Outlook
      • 7.3.2.1. Market Size & Forecast
        • 7.3.2.1.1. By Value
      • 7.3.2.2. Market Share & Forecast
        • 7.3.2.2.1. By Product
        • 7.3.2.2.2. By Application
        • 7.3.2.2.3. By End User
    • 7.3.3. United Kingdom Short-Read Sequencing Market Outlook
      • 7.3.3.1. Market Size & Forecast
        • 7.3.3.1.1. By Value
      • 7.3.3.2. Market Share & Forecast
        • 7.3.3.2.1. By Product
        • 7.3.3.2.2. By Application
        • 7.3.3.2.3. By End User
    • 7.3.4. Italy Short-Read Sequencing Market Outlook
      • 7.3.4.1. Market Size & Forecast
        • 7.3.4.1.1. By Value
      • 7.3.4.2. Market Share & Forecast
        • 7.3.4.2.1. By Product
        • 7.3.4.2.2. By Application
        • 7.3.4.2.3. By End User
    • 7.3.5. Spain Short-Read Sequencing Market Outlook
      • 7.3.5.1. Market Size & Forecast
        • 7.3.5.1.1. By Value
      • 7.3.5.2. Market Share & Forecast
        • 7.3.5.2.1. By Product
        • 7.3.5.2.2. By Application
        • 7.3.5.2.3. By End User

8. Asia Pacific Short-Read Sequencing Market Outlook

  • 8.1. Market Size & Forecast
    • 8.1.1. By Value
  • 8.2. Market Share & Forecast
    • 8.2.1. By Product
    • 8.2.2. By Application
    • 8.2.3. By End User
    • 8.2.4. By Country
  • 8.3. Asia Pacific: Country Analysis
    • 8.3.1. China Short-Read Sequencing Market Outlook
      • 8.3.1.1. Market Size & Forecast
        • 8.3.1.1.1. By Value
      • 8.3.1.2. Market Share & Forecast
        • 8.3.1.2.1. By Product
        • 8.3.1.2.2. By Application
        • 8.3.1.2.3. By End User
    • 8.3.2. India Short-Read Sequencing Market Outlook
      • 8.3.2.1. Market Size & Forecast
        • 8.3.2.1.1. By Value
      • 8.3.2.2. Market Share & Forecast
        • 8.3.2.2.1. By Product
        • 8.3.2.2.2. By Application
        • 8.3.2.2.3. By End User
    • 8.3.3. Japan Short-Read Sequencing Market Outlook
      • 8.3.3.1. Market Size & Forecast
        • 8.3.3.1.1. By Value
      • 8.3.3.2. Market Share & Forecast
        • 8.3.3.2.1. By Product
        • 8.3.3.2.2. By Application
        • 8.3.3.2.3. By End User
    • 8.3.4. South Korea Short-Read Sequencing Market Outlook
      • 8.3.4.1. Market Size & Forecast
        • 8.3.4.1.1. By Value
      • 8.3.4.2. Market Share & Forecast
        • 8.3.4.2.1. By Product
        • 8.3.4.2.2. By Application
        • 8.3.4.2.3. By End User
    • 8.3.5. Australia Short-Read Sequencing Market Outlook
      • 8.3.5.1. Market Size & Forecast
        • 8.3.5.1.1. By Value
      • 8.3.5.2. Market Share & Forecast
        • 8.3.5.2.1. By Product
        • 8.3.5.2.2. By Application
        • 8.3.5.2.3. By End User

9. Middle East & Africa Short-Read Sequencing Market Outlook

  • 9.1. Market Size & Forecast
    • 9.1.1. By Value
  • 9.2. Market Share & Forecast
    • 9.2.1. By Product
    • 9.2.2. By Application
    • 9.2.3. By End User
    • 9.2.4. By Country
  • 9.3. Middle East & Africa: Country Analysis
    • 9.3.1. Saudi Arabia Short-Read Sequencing Market Outlook
      • 9.3.1.1. Market Size & Forecast
        • 9.3.1.1.1. By Value
      • 9.3.1.2. Market Share & Forecast
        • 9.3.1.2.1. By Product
        • 9.3.1.2.2. By Application
        • 9.3.1.2.3. By End User
    • 9.3.2. UAE Short-Read Sequencing Market Outlook
      • 9.3.2.1. Market Size & Forecast
        • 9.3.2.1.1. By Value
      • 9.3.2.2. Market Share & Forecast
        • 9.3.2.2.1. By Product
        • 9.3.2.2.2. By Application
        • 9.3.2.2.3. By End User
    • 9.3.3. South Africa Short-Read Sequencing Market Outlook
      • 9.3.3.1. Market Size & Forecast
        • 9.3.3.1.1. By Value
      • 9.3.3.2. Market Share & Forecast
        • 9.3.3.2.1. By Product
        • 9.3.3.2.2. By Application
        • 9.3.3.2.3. By End User

10. South America Short-Read Sequencing Market Outlook

  • 10.1. Market Size & Forecast
    • 10.1.1. By Value
  • 10.2. Market Share & Forecast
    • 10.2.1. By Product
    • 10.2.2. By Application
    • 10.2.3. By End User
    • 10.2.4. By Country
  • 10.3. South America: Country Analysis
    • 10.3.1. Brazil Short-Read Sequencing Market Outlook
      • 10.3.1.1. Market Size & Forecast
        • 10.3.1.1.1. By Value
      • 10.3.1.2. Market Share & Forecast
        • 10.3.1.2.1. By Product
        • 10.3.1.2.2. By Application
        • 10.3.1.2.3. By End User
    • 10.3.2. Colombia Short-Read Sequencing Market Outlook
      • 10.3.2.1. Market Size & Forecast
        • 10.3.2.1.1. By Value
      • 10.3.2.2. Market Share & Forecast
        • 10.3.2.2.1. By Product
        • 10.3.2.2.2. By Application
        • 10.3.2.2.3. By End User
    • 10.3.3. Argentina Short-Read Sequencing Market Outlook
      • 10.3.3.1. Market Size & Forecast
        • 10.3.3.1.1. By Value
      • 10.3.3.2. Market Share & Forecast
        • 10.3.3.2.1. By Product
        • 10.3.3.2.2. By Application
        • 10.3.3.2.3. By End User

11. Market Dynamics

  • 11.1. Drivers
  • 11.2. Challenges

12. Market Trends & Developments

  • 12.1. Merger & Acquisition (If Any)
  • 12.2. Product Launches (If Any)
  • 12.3. Recent Developments

13. Global Short-Read Sequencing Market: SWOT Analysis

14. Porter's Five Forces Analysis

  • 14.1. Competition in the Industry
  • 14.2. Potential of New Entrants
  • 14.3. Power of Suppliers
  • 14.4. Power of Customers
  • 14.5. Threat of Substitute Products

15. Competitive Landscape

  • 15.1. Illumina, Inc.
    • 15.1.1. Business Overview
    • 15.1.2. Products & Services
    • 15.1.3. Recent Developments
    • 15.1.4. Key Personnel
    • 15.1.5. SWOT Analysis
  • 15.2. Invitae Corporation
  • 15.3. Thermo Fisher Scientific, Inc.
  • 15.4. Pacific Biosciences of California, Inc.
  • 15.5. BGI Genomics Co., Ltd
  • 15.6. QIAGEN NV
  • 15.7. Agilent Technologies, Inc.
  • 15.8. Azenta US, Inc.
  • 15.9. PerkinElmer, Inc.
  • 15.10. ProPhase Labs, Inc.

16. Strategic Recommendations

17. About Us & Disclaimer